As domestic pharmaceutical companies' ability to innovate at the source continues to improve, the global commercialization system continues to improve, and industrial policies continue to improve, the asset value of high-quality innovative drugs with core competitiveness will eventually return. According to statistics from the Securities Times and Databao, according to the performance data currently disclosed, there are 112 biomedical stocks whose net profit increased by more than 20% year-on-year in the first half of 2026, according to the lower limit of semi-annual reports, performance reports, and forecasted net profit.

As domestic pharmaceutical companies' ability to innovate at the source continues to improve, the global commercialization system continues to improve, and industrial policies continue to improve, the asset value of high-quality innovative drugs with core competitiveness will eventually return. According to statistics from the Securities Times and Databao, according to the performance data currently disclosed, there are 112 biomedical stocks whose net profit increased by more than 20% year-on-year in the first half of 2026, according to the lower limit of semi-annual reports, performance reports, and forecasted net profit.